ImmuneRegen BioSciences, Inc. Signs Lovelace Respiratory Research Institute as Development and Regulatory Partner

Published: Feb 19, 2008

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), today announced it has finalized an agreement with Lovelace Respiratory Research Institute (LRRI) in Albuquerque, N.M., to provide a broad range of product development services pertaining to inhalation and intranasal drug delivery, and associated regulatory affairs support. This strategic relationship is expected to support ImmuneRegen’s preparation for an Investigational New Drug Application (IND) for Homspera™.

Back to news